首页 | 本学科首页   官方微博 | 高级检索  
相似文献
 共查询到20条相似文献,搜索用时 15 毫秒
1.
We identified novel potent inhibitors of p38 mitogen-activated protein (MAP) kinase using a structure-based design strategy, beginning with lead compound, 3-(butan-2-yl)-6-(2,4-difluoroanilino)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one ( 1 ). To enhance the inhibitory activity of 1 against production of tumor necrosis factor-α (TNF-α) in human whole blood (hWB) cell assays, we designed and synthesized hybrid compounds in which the imidazo[4,5-b]pyridin-2-one core was successfully linked with the p-methylbenzamide fragment. Among the compounds evaluated, 3-(3-tert-butyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-6-yl)-4-methyl-N-(1-methyl-1H-pyrazol-3-yl)benzamide ( 25 ) exhibited potent p38 inhibition, superior suppression of TNF-α production in hWB cells, and also significant in vivo efficacy in a rat model of collagen-induced arthritis (CIA). In this paper, we report the discovery of potent, selective, and orally bioavailable imidazo[4,5-b]pyridin-2-one-based p38 MAP kinase inhibitors.  相似文献   

2.
The p38 mitogen‐activated protein (MAP) kinase α plays a central role in the regulation of cellular responses such as differentiation, proliferation, apoptosis, and inflammation. Inhibition of p38 results in decreased synthesis of pro‐inflammatory cytokines. To date, diverse p38α inhibitors are in phase II clinical trials for numerous cytokine‐dependent diseases. 2‐Sulfanylimidazole derivatives offer advantages over the prototype inhibitor SB 203580, including fewer cytochrome P450 interactions and better kinetic properties. The aim of this study was to develop novel 1,2,4,5‐tetrasubstituted pyridinylimidazoles with acyl residues at the imidazole N1 position that can interact with the kinase's hydrophobic region II (HR II) or sugar pocket (SP) to improve both selectivity and activity. The substitution pattern was optimized by variation of the acyl moiety at the N1 position of the N‐aminoimidazole core. Acylation of the amino function was used for optimization and led to potent p38α MAPK inhibitors.  相似文献   

3.
Targeting cytokines has become an important focus in the treatment of many inflammatory disorders. p38 MAP kinase (MAPK) is the key enzyme in regulating the biosynthesis and release of pro‐inflammatory cytokines such as IL‐1β and TNFα. Inhibition of p38 MAPK results in decreased expression of these cytokines. Tri‐ and tetrasubstituted pyridinylimidazoles are potent inhibitors of p38 MAPK. Substitution on the pyridinyl moiety allows the design of inhibitors that show increased selectivity and activity by targeting the enzyme's hydrophobic region II. The objective of this study was to synthesize novel 1,2,4,5‐tetrasubstituted imidazole derivates and to characterize them not only for their ability to inhibit p38 MAPK and modulate cytokine release in human whole blood, but also to evaluate their metabolic stability. Biological data and metabolic studies demonstrate that the introduction of a 2‐acylamino function at C2 of the pyridine results in highly efficient and metabolically stable inhibitors relative to C2‐alkylamino derivatives. A series of novel candidates was investigated for metabolic stability in human liver microsomes and in human whole blood. Additionally, metabolic S‐oxidation was investigated, and possible metabolites were synthesized.  相似文献   

4.
2-巯基-5-甲氧基咪唑并[4,5-b]吡啶的合成工艺   总被引:3,自引:0,他引:3       下载免费PDF全文
对新型质子泵抑制剂泰妥拉唑的关键中间体2-巯基-5-甲氧基咪唑并[4,5-b]吡啶的合成工艺进行了研究,以2,6-二氯吡啶为原料,先硝化得到2,6-二氯-3-硝基吡啶,然后经胺化得2-氨基-3-硝基-6-氯吡啶,再与甲醇钠反应得2-氨基-3-硝基-6-甲氧基吡啶,用铁粉还原得2,3-二氨基-6-甲氧基吡啶,最后与二硫化碳环化制得标题化合物。各步反应的最佳反应条件(反应温度,反应时间,摩尔收率)分别为,硝化: 110℃, 8 h, 79.3%; 胺化:室温, 10 h, 87.6%; 甲氧基化:65℃, 30min, 98.7%; 还原:回流, 3hrs; 环化:回流, 4hrs, 71.3%(还原及环化两步)。 标题化合物熔点与文献报道一致,并通过1H NMR进一步确证结构。  相似文献   

5.
该文以2,6-二氯吡啶为原料,用甲醇/氢氧化钠体系进行甲氧基取代,用硝酸钾/浓硫酸进行硝化反应,再用氨水氨解,制得2-氨基-3-硝基-6-甲氧基吡啶(III),最后用氯化亚锡在75℃下反应4h还原III,再用二硫化碳环化合成2-巯基-5-甲氧基咪唑并[4,5-b]吡啶,总收率为43.6%。产物结构用IR、1HNMR和MS作了表征。  相似文献   

6.
以2,6-二氯吡啶为原料,用甲醇/氢氧化钠体系进行甲氧基取代,用硝酸钾/浓硫酸进行硝化反应,再用氨水氨解,制得2-氨基-3-硝基-6-甲氧基吡啶(Ⅲ),最后用氯化亚锡于75℃反应4h还原Ⅲ,再用二硫化碳环化合成2-巯基-5-甲氧基咪唑并[4,5-b]吡啶,总收率为43.6%。产物结构用IR、1HNMR和MS作了表征。  相似文献   

7.
根据已有的具有抗肿瘤活性的咪唑[2,1-b]并-1,3,4-噻二唑类化合物的结构及其构效关系,以2-氨基-5-苯基-1,3,4-噻二唑和溴代乙酰乙酸乙酯为原料设计并合成了8个6-甲基-2-苯基咪唑[2,1-b]并-1,3,4-噻二唑-5-碳酰肼的腙类衍生物.通过1HNMR、LC-MS、IR等方法对其结构进行了确证.  相似文献   

8.
Synthesis of 2-triazolylthiazolo[4,5-b]quinoxaline derivatives was achieved by diazotisation of 2-aminothiazolo[4,5-b]quinoxaline and its 6-nitro derivative using orthophosphoric acid and sodium nitrite with a trace of nitric acid, coupling with suitable aromatic amines and subsequent cyclisation of the resulting ortho amino azo compounds. Diazotisation of 2,6-diaminothiazolo[4,5-b]quinoxaline with concentrated hydrochloric acid and sodium nitrite and subsequent coupling and cyclisation resulted in the 6-triazolylthiazolo[4,5-b]quinoxaline derivatives. These compounds were applied on polyester as fluorescent disperse dyes.  相似文献   

9.
《Journal of Sulfur Chemistry》2013,34(4-5):405-410
Pyrimido[1,2-b][1,2,4,5]tetrazin-6-one, tetrazino[3,2-b]quinazolin-5-one, pyrimidino[1,2-b]1,2,4,5-tetrazin-5-one and triazolo[4,3-a]pyrimidine derivatives were synthesized from C-(4-methyl-2-phenyl)thiazol-5-oyl-N-phenyl-hydrazonoyl bromide and different pyrimidine-2-thiones. New compounds had their structures confirmed by elemental and spectral analysis and were screened antimicrobial activity.  相似文献   

10.
A series of new 2-arylthio-3-ethoxycarbonyl-6-arylimidazo[2,1-b]thiazoles (4a4h) and 2-arenesulfonyl-3-ethoxycarbonyl-6-arylimidazo[2,1-b]thiazoles (5a5h) have been prepared and characterized by analytical and spectral methods. The title compounds 4a4h and 5a5h were obtained by the reaction of 2-amino-4-ethoxycarbonyl-5-arylthiothiazoles (2a and 2b)/2-amino-4-ethoxycarbonyl-5-arenesulphonyl-thiazoles (3a and 3b) with various phenacyl bromides in anhydrous ethanol. These newly synthesized compounds (4a4h and 5a5h) were screened for their antibacterial activity against Gram-negative bacterium Escherichia coli, Gram-positive bacterium Staphylococcus aureus, and antifungal properties against Aspergillus niger and Candida albicans.  相似文献   

11.
12.
Urolithins (hydroxylated 6H-benzo[c]chromen-6-ones) are the main bioavailable metabolites of ellagic acid (EA), which was shown to be a cognitive enhancer in the treatment of neurodegenerative diseases. As part of this research, a series of alkoxylated 6H-benzo[c]chromen-6-one derivatives were designed and synthesized. Furthermore, their biological activities were evaluated as potential PDE2 inhibitors, and the alkoxylated 6H-benzo[c]chromen-6-one derivative 1f was found to have the optimal inhibitory potential (IC50: 3.67 ± 0.47 μM). It also exhibited comparable activity in comparison to that of BAY 60-7550 in vitro cell level studies.  相似文献   

13.
A series of 2-aminothiazole derivatives were designed, synthesized on the basis of bioisosterism strategy and evaluated for their CHK1 inhibitory activity. Most of them exhibited potent CHK1 inhibition, and excellent antiproliferative activity against MV-4-11 and Z-138 cell lines. Systematic structure-activity relationship (SAR) efforts led to the discovery of a promising compound 8 n , which showed potent CHK1 inhibitory activity with IC50 value of 4.25±0.10 nM, excellent antiproliferative activity against MV-4-11 and Z-138 cells with IC50 value of 42.10±5.77 nM and 24.16±6.67 nM, respectively, as well as moderate oral exposure (AUC(0−t)=1076.25 h ⋅ ng/mL) in mice. Additionally, treatment of MV-4-11 cells with compound 8 n for 2 h led to robust inhibition of CHK1 autophosphorylation on serine 296. Furthermore, kinase selectivity assay revealed that 8 n displayed acceptable selectivity toward 15 kinases. These results demonstrated that compound 8 n may be a promising potential anticancer agent for further development.  相似文献   

14.
为寻找高活性的乙酰胆碱酯酶(AChE)抑制剂,以取代的苯甲醛和N-乙酰甘氨酸为原料经过五步反应合成了13个2H-噻唑[3,2-b][1,2,4]三嗪-3,7-二酮类化合物,目标化合物结构经1H NMR,13C NMR和HRMS确认。采用Ellman法测试了化合物在10 μmol/L浓度下对AChE的抑制活性,结果显示所有目标化合物均具有抑制活性,其中化合物6-(4-甲氧基苄基)-2-(4-甲氧基苯亚甲基)-2H-噻唑并[3,2-b]-1,2,4-三嗪-3,7-二酮(Ⅴk)活性最好,抑制率达到80.1%。通过分子对接研究了化合物Ⅴk和AChE的结合模式,Ⅴk可以跟AChE的多个催化位点结合。2H-噻唑[3,2-b][1,2,4]三嗪-3,7-二酮类化合物可以为开发具有自主知识产权的新型AChE抑制剂提供参考。  相似文献   

15.
以6-氟-色满酮-4为原料,与6-氨基胡椒醛发生Friedǎnder合反应而得到新的喹啉衍生物2-氟-9,10-亚甲二氧基-6[H]-[1]苯并吡喃并〔4,3-b]喹啉,其结构经IR、^1HNMR、MS和元素分析确证。  相似文献   

16.
以3 羟甲基吡啶为起始原料,采用碳酰二咪唑(CDI)法在0~10℃下搅拌反应,合成中间体4 [N (吡啶 3 甲氧羰基)氨甲基]苯甲酸(Ⅰ),收率为83 9%;然后与氯甲酸乙酯及三乙胺在0~10℃下搅拌反应,制得酸酐活性中间体(Ⅱ);它不经分离直接与邻苯二胺在室温条件下反应10h即得目标产物:N (2 氨苯基) 4 [N (吡啶 3 甲氧羰基)氨甲基]苯甲酰胺,经硅胶柱层析提纯后,收率为45 0%,总收率为37 8%,合成具有一定绿色化学特性;经质谱、核磁和红外等谱学方法鉴定了目标分子结构。  相似文献   

17.
以缬草酸内酯(1,4-戊内酯)为原料,合成中间体3-(3-羟丁基)-4-氨基-5-巯基-1,2,4-三唑1;1与ω-卤代的芳酮缩合得到了8个全新三唑并噻二嗪类化合物2a-2h,其结构经1H NMR和Ms进行了表征。  相似文献   

18.
Reversible protein kinase inhibitors that bind in the ATP cleft can be classified as type I or type II binders. Of these, type I inhibitors address the active form, whereas type II inhibitors typically lock the kinase in an inactive form. At the molecular level, the conformation of the flexible activation loop holding the key DFG motif controls access to the ATP site, thereby determining an active or inactive kinase state. Accordingly, type I and type II kinase inhibitors bind to so‐called DFG‐in or DFG‐out conformations, respectively. Based on our former study on highly selective platelet‐derived growth factor receptor β (PDGFRβ) pyrazin‐2‐one type I inhibitors, we expanded this scaffold toward the deep pocket, yielding the highly potent and effective type II inhibitor 5 (4‐[(4‐methylpiperazin‐1‐yl)methyl]‐N‐[3‐[[6‐oxo‐5‐(3,4,5‐trimethoxyphenyl)‐1H‐pyrazin‐3‐yl]methyl]phenyl]benzamide). In vitro characterization, including selectivity panel data from activity‐based assays (300 kinases) and affinity‐based assays (97 kinases) of these PDGFRβ type I ( 1 ; 5‐(4‐hydroxy‐3‐methoxy‐phenyl)‐3‐(3,4,5‐trimethoxyphenyl)‐1H‐pyrazin‐2‐one) and II ( 5 ) inhibitors showing the same pyrazin‐2‐one chemotype are compared. Implications are discussed regarding the data for selectivity and efficacy of type I and type II ligands.  相似文献   

19.
介绍了在碱催化条件下以对硝基苯甲腈为起始原料,醇解生成对硝基苯甲亚胺酸甲酯,继而氨化、肟化一锅反应,并采用氢化还原的方法最终合成2-(4-氨基苯基)-6-叔丁基-1H-吡唑[1,5-b][1,2,4]三唑,总收率达68.6%。  相似文献   

20.
3-(4-Bromophenyl)-2-cyanoprop-2-enethioamide (1) reacted with ethyl 3-oxo-3-phenylpropanoate (2) to give ethyl 4-(4-bromophenyl)-5-cyano-2-phenyl-6-thioxo-1,6-dihydropyridine-3-carboxylate (3). Compound 3 was taken as a starting material for the synthesis of thio-substituted ethyl nicotinate derivatives 5ad, which underwent cyclization to the corresponding thieno[2,3-b]pyridines 6ad. Also 3 reacted with hydrazine hydrate to give the pyrazolo[3,4-b]pyridine derivative 7, which upon diazotization gave the diazonium derivative 8. Compound 6a condensed with dimethylformamide–dimethylacetal to afford thieno[2,3-b]pyridine derivative 9, which reacted with different amines 10ae to afford the pyridothienopyrimidine derivatives 12ae through the Dimroth rearrangement. Moreover, compound 6a reacted with different reagents to give pyridothienopyrimidine derivatives 14a and b, 17 and pyrazolothienopyridine derivative 18. In addition, acetylating compound 6c with chloroacetylchloride afforded the 3-[(2)-chloroacetylamino]thieno[2,3-b]pyridine derivative 20, which upon cyclization yielded the corresponding 2-chloromethylpyrido[3′,2′:4,5]thieno[3,2-d]pyrimidine derivative 21. Some of the newly synthesized compounds were screened in vitro for their antimicrobial activities.

  相似文献   

设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号